BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2025-09
206 industry Phase 2/3 trial readout(s) and 31 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2025-09 est. | P1/P2 | Chung Mei Biopharma Co., Ltd | NCT02994498 Safety and Efficacy of DCB-BO1301 in Advanced Melanoma | Advanced Melanoma | unknown | 33 |
| 2025-09 est. | P2 | Aphios | NCT03813095 Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction | Addiction; Opioid Dependence; Opioid Withdrawal | unknown | 32 |
| 2025-09 est. | P3 | Hinova Pharmaceuticals Inc. | NCT03851640 A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC). | MCRPC | recruiting | 417 |
| 2025-09 est. | P2 | Replimune, Inc. REPL | NCT04050436 Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer | Cutaneous Squamous Cell Carcinoma; Advanced Cutaneous Squamous Cell Carcinoma; Metastatic Cutaneous | active not recruiting | 231 |
| 2025-09 est. | P1/P2 | Aegle Therapeutics | NCT04173650 MSC EVs in Dystrophic Epidermolysis Bullosa | Dystrophic Epidermolysis Bullosa | recruiting | 8 |
| 2025-09 est. | P1/P2 | Kahr Medical | NCT04440735 A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors | Advanced Solid Tumor; Non Small Cell Lung Cancer; Colorectal Cancer | active not recruiting | 125 |
| 2025-09 est. | P1/P2 | Dynacure | NCT04743557 Early Phase Human Drug Trial to Investigate DYN101 in Participants 2 to 17 Years With Centronuclear Myopathies | Centronuclear Myopathy | withdrawn | |
| 2025-09 est. | P2 | 4SC AG | NCT04874831 Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1) | Merkel Cell Carcinoma | withdrawn | |
| 2025-09 est. | P1/P2 | Akeso | NCT04900350 A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome | Myelodysplastic Syndrome | active not recruiting | 136 |
| 2025-09 est. | P1/P2 | Eutilex | NCT04903873 A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors | Solid Tumor; Renal Cell Cancer Metastatic; Non-Small Cell Lung Cancer; Renal Cell Carcinoma; Prostat | unknown | 110 |
| 2025-09 est. | P2 | Kibow Pharma | NCT04913272 Clinical Trial To Evaluate Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With Chronic Kidney Disease Stage IV | Chronic Kidney Disease stage4 | suspended | 630 |
| 2025-09 est. | P1/P2 | Akeso | NCT04980885 A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia | Acute Myeloid Leukemia | active not recruiting | 68 |
| 2025-09 est. | P1/P2 | Xuanzhu Biopharmaceutical Co., Ltd. | NCT04996121 A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors | Locally Advanced or Metastatic Solid Tumors; Locally Advanced or Metastatic Non-small Cell Lung Canc | recruiting | 360 |
| 2025-09 est. | P3 | Bausch Health Americas, Inc. | NCT05071716 Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | Hepatic Encephalopathy | active not recruiting | 524 |
| 2025-09 est. | P1/P2 | Ascentage Pharma Group Inc. AAPG | NCT05186012 APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma | NHL, Adult | unknown | 51 |
| 2025-09 est. | P2 | Partner Therapeutics, Inc. | NCT05284214 Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors | Solid Tumor; Solid Tumor, Adult | withdrawn | |
| 2025-09 est. | P1/P2 | SCG Cell Therapy Pte. Ltd. | NCT05417932 A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma | Hepatitis B Virus Related Hepatocellular Carcinoma; Hepatocellular Carcinoma Recurrent | recruiting | 46 |
| 2025-09 est. | P2 | Qu Biologics Inc. | NCT05421325 Efficacy of QBKPN Site-Specific Immunomodulator in Improving Innate Immune Function & Reducing Respiratory Tract Infection in Older Adults | Immune Deficiency | recruiting | 72 |
| 2025-09 est. | P1/P2 | Editas Medicine, Inc. EDIT | NCT05444894 EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT) | Transfusion Dependent Beta Thalassemia; Hemoglobinopathies; Thalassemia Major; Thalassemia Intermedi | active not recruiting | 9 |
| 2025-09 est. | P3 | EMS | NCT05542173 Efficacy and Safety of BALI Association in the Treatment of Aphthous Ulcerations | Aphthous Stomatitis | unknown | 232 |
| 2025-09 est. | P2 | COMPASS Pathways CMPS | NCT05733546 A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Partic | Major Depressive Disorder | active not recruiting | 102 |
| 2025-09 est. | P1/P2 | Biocad | NCT05747261 Study of the Safety and Efficacy of an Adeno-Associated Viral Vector Carrying the SMN Gene After a Single Intravenous Administration of Escalating Doses in Chil | Spinal Muscular Atrophy (SMA) | recruiting | 40 |
| 2025-09 est. | P3 | Areteia Therapeutics | NCT05748600 A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma | Eosinophilic Asthma; Asthma; Eosinophilic; Asthma Attack | active not recruiting | 600 |
| 2025-09 est. | P3 | Polpharma Biologics S.A. | NCT05771155 Efficacy, Safety and Immunogenicity of the Proposed Biosimilar Vedolizumab PB016 in Comparison With Entyvio® | Ulcerative Colitis | unknown | 750 |
| 2025-09 est. | P2 | George Medicines PTY Limited | NCT05833958 Polypill Versus Metformin in New Onset Type 2 Diabetes | Type 2 Diabetes | withdrawn | |
| 2025-09 est. | P3 | Recardio, Inc. | NCT05881382 Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction | ST Elevation Myocardial Infarction | unknown | 4100 |
| 2025-09 est. | P3 | Natural Wellness Egypt | NCT06140485 A Trial to Investigate the Efficacy and Safety of NW Low-Glu® in Patients With Type II Diabetes Mellitus | Diabetes Mellitus, Type 2 | unknown | 400 |
| 2025-09 est. | P3 | Daewoong Pharmaceutical Co. LTD. | NCT06141980 Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes Mellitus | T2DM (Type 2 Diabetes Mellitus) | unknown | 134 |
| 2025-09 est. | P2 | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) | NCT06233903 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System | Neuroblastoma; Pheochromocytoma; Paraganglioma | withdrawn | |
| 2025-09 est. | P3 | Addpharma Inc. | NCT06441630 A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B | Essential Hypertension | recruiting | 251 |
| 2025-09 est. | P1/P2 | Nimble Diagnostics S.L. | NCT06968858 Pilot Study of the α Prototype NIMBLE System: Feasibility, Safety, and Initial Performance in Non-Invasive Detection of Coronary In-Stent Restenosis | In-stent Restenosis; Stent Fracture; Stent Complication | recruiting | 30 |
| 2025-09-01 | P3 | Alector Inc. ALEC | NCT04374136 A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3) | Frontotemporal Dementia | terminated | 119 |
| 2025-09-01 | P1/P2 | Bristol-Myers Squibb BMY | NCT05134948 A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors | Advanced Solid Tumors | completed | 24 |
| 2025-09-01 | P2 | Intercept Pharmaceuticals | NCT05239468 Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC | Primary Biliary Cholangitis | completed | 72 |
| 2025-09-01 est. | P1/P2 | RemeGen Co., Ltd. | NCT05821933 RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC | NSCLC | unknown | 106 |
| 2025-09-01 | P2 | MAXVAX Biotechnology Limited Liability Company | NCT05856084 Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above | Herpes Zoster | completed | 924 |
| 2025-09-01 | P3 | Meiji Seika Pharma Co., Ltd. | NCT05905055 P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem | Complicated Urinary Tract Infection; Acute Pyelonephritis; Hospital-acquired Bacterial Pneumonia; Ve | completed | 126 |
| 2025-09-01 | P3 | Alector Inc. ALEC | NCT06111014 Continuation Study for Latozinemab | Neurodegenerative Diseases | terminated | 17 |
| 2025-09-01 | P2 | GemVax & Kael | NCT06235775 Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011 | Progressive Supranuclear Palsy | completed | 67 |
| 2025-09-01 est. | P3 | Chengdu CoenBiotech Co., Ltd | NCT06241755 Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle In | Non-Muscle Invasive Bladder Cancer | unknown | 412 |
| 2025-09-01 est. | P2 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | NCT06246565 A Study of HS-10383 in Chinese Adult Subjects With Refractory or Unexplained Chronic Cough (RUCC) | Cough | unknown | 276 |
| 2025-09-01 est. | P2 | Neuroventi Inc. | NCT06951854 Phase II Clinical Trial to Evaluate the Efficacy and Safety of NV01-A02 in Children With Autism Spectrum Disorder | Autism Spectrum Disorder (ASD | recruiting | 105 |
| 2025-09-01 est. | P3 | Shanghai Cingularbio Co. Ltd | NCT06968221 Bovine Reinforcement in Stomach, Colorectal and Lung Operation | Rectal Cancer Stage III; Lung Cancer Stage III | recruiting | 172 |
| 2025-09-01 | P2 | Bharat Biotech International Limited | NCT06997367 Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine MTBVAC in Healthy Indian Adults and Adolescents (BBV169/2024) | Tuberculosis (TB) | active not recruiting | 164 |
| 2025-09-02 | P2/P3 | Tetra Discovery Partners | NCT05163808 A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome | Fragile X Syndrome | completed | 163 |
| 2025-09-02 | P3 | AbbVie ABBV | NCT05652205 A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation | Functional Constipation (FC); Chronic Idiopathic Constipation (CIC) | completed | 123 |
| 2025-09-02 | P2 | Boehringer Ingelheim | NCT06139328 IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack | Myocardial Infarction | terminated | 160 |
| 2025-09-02 | P2 | Cardurion Pharmaceuticals, Inc. | NCT06215586 Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF) | Heart Failure; Heart Failure Preserved Ejection Fraction; Cardiovascular Diseases; Heart Diseases | completed | 303 |
| 2025-09-02 | P3 | GlaxoSmithKline | NCT06261957 A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in P | Asthma | completed | 471 |
| 2025-09-02 | P2 | Boehringer Ingelheim | NCT06360094 A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis; Progressive Pulmonary Fibrosis | terminated | 85 |
| 2025-09-02 | P3 | MoonLake Immunotherapeutics AG MLTX | NCT06411899 A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppura | Hidradenitis Suppurativa | completed | 422 |
| 2025-09-03 | P3 | Faraday Pharmaceuticals, Inc. CPPKF | NCT04837001 Evaluation in STEMI Patients Using FDY-5301 | Acute Myocardial Infarction; STEMI; Percutaneous Coronary Revascularization | completed | 2351 |
| 2025-09-03 | P2 | Forma Therapeutics, Inc. | NCT04987489 A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease | Sickle Cell Disease; Thalassemia | completed | 53 |
| 2025-09-03 | P2 | Hoffmann-La Roche | NCT05419375 Screening Study for Participants With Malignant Tumors | Solid Tumors | completed | 470 |
| 2025-09-03 | P2 | Merck Sharp & Dohme LLC MRK | NCT05508867 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodg | Hodgkin Lymphoma | completed | 203 |
| 2025-09-03 | P3 | Biofrontera Inc. BFRI | NCT05662202 Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and | Actinic Keratoses | completed | 172 |
| 2025-09-04 | P3 | Apellis Pharmaceuticals, Inc. | NCT03531255 Pegcetacoplan Long Term Safety and Efficacy Extension Study | PNH | completed | 137 |
| 2025-09-04 | P1/P2 | Hoffmann-La Roche | NCT05251948 An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma | Gastric and Gastroesophageal Junction Carcinoma | terminated | 40 |
| 2025-09-04 | P2 | Janssen Research & Development, LLC | NCT05379634 A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies | Myositis | completed | 36 |
| 2025-09-04 | P3 | Hoffmann-La Roche | NCT05627557 A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome | Childhood Idiopathic Nephrotic Syndrome | completed | 85 |
| 2025-09-04 | P3 | Vertex Pharmaceuticals Incorporated VERX | NCT05882357 Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age | Cystic Fibrosis | completed | 67 |
| 2025-09-04 | P2 | Enyo Pharma | NCT06425055 Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1) | Alport Syndrome | completed | 26 |
| 2025-09-05 | P1/P2 | Elevar Therapeutics | NCT04526106 REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors | FGFR2 Amplification; FGFR2 Gene Mutation; FGFR2 Gene Fusion/Rearrangement; FGFR2 Gene Translocation; | completed | 490 |
| 2025-09-05 | P3 | Hoffmann-La Roche | NCT04586023 Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) | Relapsing Multiple Sclerosis | active not recruiting | 751 |
| 2025-09-05 | P1/P2 | Arcus Biosciences, Inc. RCUS | NCT04660812 An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. | Metastatic Colorectal Cancer | completed | 227 |
| 2025-09-05 | P3 | Apellis Pharmaceuticals, Inc. | NCT04770545 An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD | Geographic Atrophy Secondary to Age-related Macular Degeneration | completed | 792 |
| 2025-09-05 | P2 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | NCT04945460 A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) | Hypertension, Pulmonary | completed | 165 |
| 2025-09-05 | P3 | Seagen, a wholly owned subsidiary of Pfizer | NCT05132582 A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer | HER2 Positive Breast Cancer | active not recruiting | 654 |
| 2025-09-05 | P2 | Avidity Biosciences, Inc. | NCT05479981 Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients | DM1; Muscular Dystrophies; Myotonic Dystrophy; Myotonic Dystrophy 1; Myotonic Disorders; Muscular Di | completed | 37 |
| 2025-09-05 | P1/P2 | Arrowhead Pharmaceuticals ARWR | NCT05537025 Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | completed | 105 |
| 2025-09-05 | P1/P2 | Pfizer PFE | NCT06206837 A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer. | Breast Cancer | active not recruiting | 71 |
| 2025-09-05 | P3 | Dong-A ST Co., Ltd. | NCT06290349 Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic | Type 2 Diabetes | active not recruiting | 174 |
| 2025-09-06 | P2 | Cytoki Pharma | NCT06611930 CK-0045 Proof-of-concept Study in Participants With Overweight / Obesity and Type 2 Diabetes | Type 2 Diabetes Mellitus (T2DM); Obesity and Overweight | terminated | 90 |
| 2025-09-06 | P3 | HALEON HLN | NCT07140341 A Clinical Study to Assess the Effectiveness of ENO Lime in Participants With Ajeerna Vyadhi (Acidity, Acid Indigestion, Indigestion, and Associated Nausea) | Indigestion Acid; Indigestion; Nausea | completed | 40 |
| 2025-09-07 est. | P1/P2 | Biotheus Inc. | NCT05862831 Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors | Advanced Solid Tumors | unknown | 285 |
| 2025-09-08 est. | P3 | Azidus Brasil | NCT06097780 Efficacy and Safety of NestaCell® in Huntington's Disease | Huntington Disease | unknown | 120 |
| 2025-09-08 | P2 | Blueprint Medicines Corporation | NCT06922448 Study of BLU-808 in Allergic Rhinoconjunctivitis | Allergic Rhinoconjunctivitis | completed | 21 |
| 2025-09-08 | P2 | Genfit | NCT06987968 A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy | Hepatic Encephalopathy; Acute on Chronic Liver Failure (ACLF); Decompensated Cirrhosis | terminated | 3 |
| 2025-09-09 | P2 | Hipra Scientific, S.L.U | NCT06234956 Safety and Immunogenicity of BIMERVAX for the Prevention of COVID-19 in Adolescents From 12 Years to Less Than 18 Years of Age. | SARS CoV 2 Infection | completed | 242 |
| 2025-09-09 | P3 | Novo Nordisk A/S NVO | NCT06323161 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal I | Type 2 Diabetes | completed | 274 |
| 2025-09-09 | P3 | Famy Life Sciences, a Viatris Company | NCT06400511 A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment | Blepharitis | terminated | 477 |
| 2025-09-10 | P1/P2 | Arrowhead Pharmaceuticals ARWR | NCT05083364 Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease | C3 Glomerulopathy; IgA Nephropathy | completed | 62 |
| 2025-09-10 | P3 | Novartis Pharmaceuticals NVS | NCT05666804 Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculop | Macular Polypoidal Choroidal Vasculopathy (PCV) | completed | 148 |
| 2025-09-10 | P3 | Novartis Pharmaceuticals NVS | NCT05767034 Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica | Polymyalgia Rheumatica | completed | 381 |
| 2025-09-10 | P1/P2 | Inmune Bio, Inc. INMB | NCT06056791 Study of INKmune in Patients With mCRPC (CaRe Prostate) | Cancer; Metastatic Castration-resistant Prostate Cancer; mCRPC | completed | 12 |
| 2025-09-10 | P2 | Zomagen Biosciences Ltd. | NCT06771115 Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity | Obesity | completed | 175 |
| 2025-09-11 | P2 | Eledon Pharmaceuticals ELDN | NCT05983770 Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation | Kidney Transplant Rejection | completed | 127 |
| 2025-09-11 | P2 | TWi Biotechnology, Inc. | NCT06285916 A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression | Depression, Postpartum; Postpartum Depression; Post-partum Depression; Postnatal Depression; Post-Na | completed | 93 |
| 2025-09-11 | P3 | UroGen Pharma Ltd. URGN | NCT06331299 A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer | Bladder Cancer; Urothelial Carcinoma; Urothelial Carcinoma Bladder | completed | 99 |
| 2025-09-11 | P2 | Guard Therapeutics AB | NCT06475274 A Phase 2b Dose Finding Study of RMC-035 in Participants Undergoing Open-chest Cardiac Surgery | Kidney Injury Following Open-Chest Cardiac Surgery | completed | 170 |
| 2025-09-11 | P3 | Bionomics Limited | NCT06510504 Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1 | Social Anxiety Disorder | completed | 370 |
| 2025-09-11 | P3 | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | NCT06552520 To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | completed | 500 |
| 2025-09-11 | P2 | Orion Corporation, Orion Pharma ORN | NCT06956495 Efficacy and Tolerability of Tasipimidine in Sleepless Patients | Insomnia | completed | 190 |
| 2025-09-12 | P2 | Zydus Therapeutics Inc. | NCT05011305 Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis | Nonalcoholic Steatohepatitis; Fibrosis | completed | 189 |
| 2025-09-12 | P2 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | NCT07052097 Clinical Trial of TQC2938 Injection in Patients With Seasonal Allergic Rhinitis | Seasonal Allergic Rhinitis | completed | 136 |
| 2025-09-14 | P3 | GlaxoSmithKline | NCT04718389 A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype | Asthma | completed | 1717 |
| 2025-09-15 | P2 | Eidos Therapeutics, a BridgeBio company | NCT03536767 Open-Label Study of AG10 in Patients With Cardiomyopathy | Amyloid Cardiomyopathy | terminated | 47 |
| 2025-09-15 | P3 | Novo Nordisk A/S NVO | NCT04777409 A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) | Early Alzheimer´s Disease | completed | 1840 |
| 2025-09-15 | P3 | Hoffmann-La Roche | NCT04963296 A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | active not recruiting | 303 |
| 2025-09-15 | P2 | Silver Creek Pharmaceuticals | NCT05585606 Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke | Acute Ischemic Stroke (AIS) | completed | 120 |
| 2025-09-15 | P3 | Cali Pharmaceuticals LLC | NCT05813847 Herniorrhaphy for Postoperative Pain | Hernia, Inguinal; Post Operative Pain | completed | 518 |
| 2025-09-15 | P2 | Ono Pharmaceutical Co., Ltd. | NCT05923866 A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy | Multiple System Atrophy (MSA) | active not recruiting | 92 |
| 2025-09-15 | P2 | LigaChem Biosciences, Inc. | NCT06004037 Study to Evaluate the Efficacy of Delpazolid as Add-on Therapy in Refractory Mycobacterium Abscessus Complex | Nontuberculous Mycobacterium Infection; Mycobacterium Abscessus Infection | completed | 24 |
| 2025-09-15 | P3 | Eli Lilly and Company LLY | NCT06109311 A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or | Type 2 Diabetes | completed | 546 |
| 2025-09-15 est. | P2 | Bright Minds Biosciences Pty Ltd DRUG | NCT06401538 BMB-101 in Absence Epilepsy and DEE | Absence Epilepsy; Jeavons Syndrome; Dravet Syndrome; Lennox Gastaut Syndrome | recruiting | 20 |
| 2025-09-16 | P3 | Novo Nordisk A/S NVO | NCT04777396 A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) | Early Alzheimer's Disease | completed | 1840 |
| 2025-09-16 | P3 | ViiV Healthcare | NCT05917509 A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months f | HIV Infections | completed | 171 |
| 2025-09-16 | P2 | Sanofi SNY | NCT06280391 A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis | Bronchiectasis | completed | 314 |
| 2025-09-16 | P3 | R-Pharm | NCT07435324 A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma | Head and Neck Squamous Cell Carcinoma | completed | 161 |
| 2025-09-17 | P3 | Hoffmann-La Roche | NCT04544449 A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | active not recruiting | 985 |
| 2025-09-17 | P3 | Novartis Pharmaceuticals NVS | NCT06042478 Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patien | Chronic Spontaneous Urticaria | active not recruiting | 470 |
| 2025-09-17 | P3 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06184568 A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity | Type 2 Diabetes; Obesity | completed | 349 |
| 2025-09-17 | P2 | Regeneron Pharmaceuticals REGN | NCT06237309 REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction | Heart Failure | terminated | 89 |
| 2025-09-18 | P3 | Hoffmann-La Roche | NCT03194893 A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer | Neoplasms | completed | 50 |
| 2025-09-18 | P2 | GlaxoSmithKline | NCT05412030 A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants | Pneumonia, Bacterial; Pneumococcal Infections; Pneumonia, Pneumococcal | completed | 388 |
| 2025-09-18 | P2 | Engrail Therapeutics INC | NCT05749055 ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder | Generalized Anxiety Disorder | completed | 252 |
| 2025-09-18 | P3 | Sanofi Pasteur, a Sanofi Company SNY | NCT06397768 Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers | RSV Immunization | terminated | 2226 |
| 2025-09-19 | P3 | Bayer | NCT04015180 Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090 | Retinopathy of Prematurity (ROP) | completed | 100 |
| 2025-09-19 | P3 | Octapharma | NCT04502030 Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients | Chronic Lymphocytic Leukemia; Hypogammaglobulinemia | completed | 247 |
| 2025-09-19 | P3 | Alexion Pharmaceuticals, Inc. | NCT04543591 Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant | Thrombotic Microangiopathy | completed | 148 |
| 2025-09-19 | P3 | Novartis Pharmaceuticals NVS | NCT04578834 Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients | IgA Nephropathy | completed | 517 |
| 2025-09-19 | P2 | Cogent Biosciences, Inc. COGT | NCT04996875 (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis | Advanced Systemic Mastocytosis (AdvSM); SM With an Associated Hematologic Neoplasm (SM-AHN); Mast Ce | recruiting | 140 |
| 2025-09-19 est. | P1/P2 | Shanghai Huaota Biopharmaceutical Co., Ltd. | NCT06056323 A Study of HB0045 Injection in Patients With Advanced Solid Tumors | Solid Tumor, Adult | unknown | 71 |
| 2025-09-19 | P2 | Novo Nordisk A/S NVO | NCT06326047 A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes | Diabetes Mellitus, Type 2 | completed | 299 |
| 2025-09-19 | P3 | Alumis Inc ALMS | NCT06586112 A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | completed | 912 |
| 2025-09-19 | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT06881264 A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes | Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs | completed | 401 |
| 2025-09-20 | P3 | Pfizer PFE | NCT05512819 A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan | Pneumococcal Disease | completed | 541 |
| 2025-09-20 | P1/P2 | InxMed (Shanghai) Co., Ltd. | NCT05994131 IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC | NSCLC | active not recruiting | 110 |
| 2025-09-22 | P2 | BioAtla, Inc. BCAB | NCT05271604 A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Head and Neck Cancer; Squamous Cell Carcinoma of Head and Neck; Recurrent Squamous Cell Carcinoma of | completed | 42 |
| 2025-09-22 | P2 | Arrowhead Pharmaceuticals ARWR | NCT05413135 Study of ARO-APOC3 in Adults With Dyslipidemia | Dyslipidemias | completed | 418 |
| 2025-09-22 | P2 | AbbVie ABBV | NCT06032546 A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency V | Human Immuno-deficiency Virus (HIV) Disease | terminated | 163 |
| 2025-09-22 est. | P2 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT06222671 A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA) | Axial Spondyloarthritis | recruiting | 180 |
| 2025-09-22 | P3 | Teikoku Seiyaku Co., Ltd. | NCT06871046 Phase III Trial to Assess the Safety and Efficacy of TK-254RX in Patients With Contusions | Contusions | completed | 221 |
| 2025-09-22 | P2 | Shionogi | NCT06928051 A Study of S-892216 in Participants With COVID-19 | COVID-19 | completed | 282 |
| 2025-09-23 | P3 | AbbVie ABBV | NCT04161885 A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in | Acute Myeloid Leukemia (AML); Cancer | terminated | 465 |
| 2025-09-23 | P1/P2 | Sunshine Lake Pharma Co., Ltd. SBFM | NCT05451602 HEC169096 in Participants With Advanced Solid Tumors | Advanced Solid Tumor | terminated | 24 |
| 2025-09-23 | P1/P2 | Pfizer PFE | NCT05703607 A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults | Shingles; Herpes Zoster Infection; Human | terminated | 484 |
| 2025-09-23 | P2 | GlaxoSmithKline | NCT06104319 Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH | Non-alcoholic Fatty Liver Disease | completed | 61 |
| 2025-09-23 | P3 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06126783 A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease | Thyroid Eye Disease, TED | completed | 91 |
| 2025-09-23 | P2 | Transcend Therapeutics | NCT06215261 An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD | Post Traumatic Stress Disorder | completed | 62 |
| 2025-09-23 | P3 | Alumis Inc ALMS | NCT06588738 A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 | Plaque Psoriasis | completed | 862 |
| 2025-09-23 | P2 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | NCT06886126 Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus | Obesity | recruiting | 240 |
| 2025-09-23 | P3 | Incepta Pharmaceuticals Ltd | NCT07025681 PK, PD, Safety and Immunogenicity Study of Erythropoietin of Incepta Pharmaceuticals Ltd With Eprex (Janssen-Cilag). | Healthy | completed | 56 |
| 2025-09-23 | P3 | Nxera Pharma Korea Co., Ltd. | NCT07028697 A Study to Evaluate the Efficacy and Safety of Daridorexant in Participants With Insomnia Disorder | Insomnia Disorder | completed | 164 |
| 2025-09-24 | P1/P2 | Merck Sharp & Dohme LLC MRK | NCT04303169 Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who | Melanoma | completed | 146 |
| 2025-09-24 est. | P2/P3 | Shanghai Henlius Biotech | NCT04547166 A Clinical Study to Evaluate Efficacy and Safety of Serplulimab(HLX10) Combined With Bevacizumab(HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Col | Metastatic Colorectal Cancer | recruiting | 568 |
| 2025-09-24 | P3 | Takeda TAK | NCT05163314 A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome | Dravet Syndrome (DS); Lennox Gastaut Syndrome (LGS) | terminated | 352 |
| 2025-09-24 | P3 | Pfizer PFE | NCT05689164 A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy. | Duchenne Muscular Dystrophy | terminated | 7 |
| 2025-09-24 est. | P2 | Shanghai Kechow Pharma, Inc. | NCT05900219 Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study | Non-small-cell Lung Cancer | unknown | 75 |
| 2025-09-24 | P2 | Novo Nordisk A/S NVO | NCT06131372 A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema | Chronic Kidney Disease; Type 2 Diabetes; Obesity | completed | 626 |
| 2025-09-24 | P2 | Sanofi SNY | NCT06444451 A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata | Alopecia Areata | terminated | 166 |
| 2025-09-24 | P2 | Minghui Pharmaceutical (Hangzhou) Ltd | NCT07181187 Phase II Clinical Trial of MH004 Ointment in Patients With Non-segmental Vitiligo | Vitiligo | completed | 156 |
| 2025-09-25 | P2 | Boehringer Ingelheim | NCT05512377 Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder | Pancreatic Neoplasms; Solid Tumors; Biliary Tract Cancer; Lung Neoplasms; Bladder Cancer | completed | 99 |
| 2025-09-25 | P3 | Cali Pharmaceuticals LLC | NCT05831449 CPL-01 in the Management of Postoperative Pain After Bunionectomy | Bunion; Post-operative Pain | completed | 616 |
| 2025-09-25 | P1/P2 | Chongqing Precision Biotech Co., Ltd | NCT06006403 Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm | Acute Myeloid Leukemia; Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Relapse Leukemia; Refr | completed | 5 |
| 2025-09-25 | P3 | Eli Lilly and Company LLY | NCT06280716 A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis | Atopic Dermatitis | completed | 301 |
| 2025-09-25 | P2 | ModernaTX, Inc. | NCT06508320 A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [S | Influenza; SARS-CoV-2 | completed | 931 |
| 2025-09-25 | P2 | Joincare Pharmaceutical Group Industry Co., Ltd | NCT07450482 Safety and Efficacy of JKN2304 Inhalation Solution in Patients With Moderate to Severe COPD | COPD (Chronic Obstructive Pulmonary Disease); COPD | completed | 42 |
| 2025-09-25 | P3 | Taejoon Pharmaceutical Co., Ltd. | NCT07723716 Evaluate the Efficacy and Safety of CTO0307 in Adults With Presbyopia | Presbyopia | completed | 167 |
| 2025-09-26 | P1/P2 | Epizyme, Inc. | NCT02875548 A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study | Diffuse Large B-cell Lymphoma (DLBCL); Follicular Lymphoma (FL); Synovial Sarcoma; Epithelioid Sarco | terminated | 58 |
| 2025-09-26 | P2 | Aravax Pty Ltd | NCT05621317 A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy | Peanut Allergy; Peanut Hypersensitivity; Peanut-Induced Anaphylaxis; Immune System Diseases | active not recruiting | 95 |
| 2025-09-26 | P2/P3 | Otsuka Pharmaceutical Development & Commercialization, Inc. | NCT05729373 A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder | Generalized Anxiety Disorder | completed | 434 |
| 2025-09-26 | P3 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT06173284 Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis | Dermatitis, Atopic | completed | 519 |
| 2025-09-26 | P3 | Eli Lilly and Company LLY | NCT06192108 A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin | Type 2 Diabetes | completed | 962 |
| 2025-09-26 | P2 | Rapport Therapeutics Inc. RAPP | NCT06377930 Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy | Focal Onset Seizures | completed | 30 |
| 2025-09-26 | P3 | Laboratorios Silanes S.A. de C.V. | NCT06863662 Efficacy and Safety of Etoricoxib/Tizanidine Versus Etoricoxib for Acute Low Back Pain Associated to Muscle Spasm | Acute Low-back Pain; Muscle Spasm; Back Pain | completed | 136 |
| 2025-09-29 | P2 | Bayer | NCT02576431 A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors | Solid Tumors Harboring NTRK Fusion | completed | 215 |
| 2025-09-29 | P2/P3 | Gilead Sciences GILD | NCT05502341 Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1) | HIV-1-infection | active not recruiting | 689 |
| 2025-09-29 | P2 | Combangio, Inc | NCT05727878 Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED | Persistent Corneal Epithelial Defect | terminated | 103 |
| 2025-09-29 | P2 | Indivior Inc. | NCT06384157 Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder | Opioid Use Disorder | completed | 300 |
| 2025-09-29 | P3 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT06434961 The Trial of SHR6508 in Secondary Hyperparathyroidism | Secondary Hyperparathyroidism | completed | 498 |
| 2025-09-29 | P3 | Achieve Life Sciences QUIT | NCT06435221 Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette Smokers | Smoking Cessation; Vaping Cessation | completed | 479 |
| 2025-09-29 | P2 | Shandong Suncadia Medicine Co., Ltd. | NCT06816264 A Study of HRS-5346 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events | Treatment of Lipoprotein Disorder | completed | 120 |
| 2025-09-30 est. | P1/P2 | Healeon Medical Inc | NCT02952131 Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells in Inflammatory Bowel Disease | Inflammatory Bowel Diseases | suspended | 100 |
| 2025-09-30 est. | P2/P3 | Alloksys Life Sciences B.V. | NCT03050476 Preventing Systemic Inflammation After Cardiac Surgery With Alkaline Phosphatase | Systemic Inflammation; Cardiopulmonary-bypass | unknown | 1250 |
| 2025-09-30 | P3 | Celgene | NCT03915769 To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis | Colitis, Ulcerative | completed | 198 |
| 2025-09-30 est. | P2 | Hoffmann-La Roche | NCT04267237 A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in P | Non-small Cell Lung Cancer (NSCLC) | withdrawn | |
| 2025-09-30 est. | P3 | EMS | NCT04666714 Efficacy and Safety of Praga Formulation in the Treatment of Neuropathic Pain | Neuropathic Pain | recruiting | 136 |
| 2025-09-30 | P2 | Inhibrx Biosciences, Inc INBX | NCT04950075 Study of INBRX-109 in Conventional Chondrosarcoma | Conventional Chondrosarcoma | active not recruiting | 206 |
| 2025-09-30 est. | P1/P2 | RemeGen Co., Ltd. | NCT05205850 A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors | Advanced Solid Tumor | recruiting | 135 |
| 2025-09-30 | P3 | Cogent Biosciences, Inc. COGT | NCT05208047 (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | Advanced Gastrointestinal Stromal Tumors; Metastatic Cancer | recruiting | 482 |
| 2025-09-30 | P2 | GPCR Therapeutics, Inc. | NCT05561751 Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myel | Multiple Myeloma | completed | 30 |
| 2025-09-30 | P2 | USWM CT, LLC | NCT05601752 ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) | Ovarian Cancer | terminated | 21 |
| 2025-09-30 est. | P3 | Abeona Therapeutics, Inc ABEO | NCT05725018 A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients | Epidermolysis Bullosa; Recessive Dystrophic Epidermolysis Bullosa; RDEB | active not recruiting | 12 |
| 2025-09-30 est. | P1/P2 | Biocity Biopharmaceutics Co., Ltd. | NCT05731518 SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | Small Cell Lung Cancer | unknown | 67 |
| 2025-09-30 est. | P2 | Abbisko Therapeutics Co, Ltd | NCT05775874 A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC | Urothelial Carcinoma | unknown | 80 |
| 2025-09-30 est. | P2 | Cardior Pharmaceuticals GmbH | NCT05953831 Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy | Heart Failure With Preserved Ejection Fraction | withdrawn | |
| 2025-09-30 | P2 | Insmed Incorporated INSM | NCT06013241 A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) | Chronic Rhinosinusitis Without Nasal Polyps | completed | 288 |
| 2025-09-30 | P2 | Eli Lilly and Company LLY | NCT06046729 A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa | Hidradenitis Suppurativa | completed | 352 |
| 2025-09-30 | P2/P3 | Amylyx Pharmaceuticals Inc. AMLX | NCT06122662 AMX0035 and Progressive Supranuclear Palsy | Progressive Supranuclear Palsy; PSP; Neurodegenerative Diseases; Atypical Parkinsonism | completed | 139 |
| 2025-09-30 est. | P1/P2 | Mabwell (Shanghai) Bioscience Co., Ltd. | NCT06175351 Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary | Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | active not recruiting | 80 |
| 2025-09-30 | P2 | NeuroSense Therapeutics Ltd. NRSN | NCT06185543 A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of Pr | Alzheimer Disease | terminated | 8 |
| 2025-09-30 | P2 | BioAegis Therapeutics Inc. | NCT06216366 Rhu-pGSN to Mitigate Proinflammatory Responses to Decompression in Healthy SCUBA Divers | Decompression Sickness | completed | 36 |
| 2025-09-30 | P1/P2 | TransCode Therapeutics RNAZ | NCT06260774 Study of TTX-MC138 in Subjects With Advanced Solid Tumors | Advanced Solid Tumor | active not recruiting | 16 |
| 2025-09-30 | P2 | GRI Bio Operations, Inc. | NCT06331624 Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF | Idiopathic Pulmonary Fibrosis; IPF | completed | 35 |
| 2025-09-30 | P2 | Inflammx Therapeutics Inc | NCT06437223 Study of Xiflam™ Treatment in Patients Post COVID-19 Infection Suffering From What is Known as Long COVID (LC) | Long COVID | completed | 16 |
| 2025-09-30 est. | P3 | Biolab Sanus Farmaceutica | NCT06564883 Hydration and Acceptability of the Genital and Skin Mucosa of a Vaginal Moisturizer in Menopausal Women | Vaginismus; Vaginal Atrophy; Menopause | unknown | 45 |
| 2025-09-30 | P2 | Invirsa, Inc. | NCT06599684 Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy | Non-center Involved Diabetic Macular Edema; Non-center Involved Diabetic Macular Edema Associated Wi | completed | 19 |
| 2025-09-30 | P2 | Zealand Pharma ZEAL.CO | NCT06662539 Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities | Obesity | completed | 493 |
| 2025-09-30 | P2 | HiDO Technologies | NCT06691256 Preventing Medication Mismanagement in People Living With Dementia Through Automated Medication Dispensing With Facial Recognition and Video Observation | Alzheimer Disease; Dementia; Medication Adherence; Type 2 Diabetes Mellitus (T2DM) | completed | 50 |
| 2025-09-30 est. | P2 | CNBG-Virogin Biotech (Shanghai) Ltd. | NCT06746480 Clinical Study of VG161 in Advanced Intrahepatic Cholangiocarcinoma | Advanced Intrahepatic Cholangiocarcinoma | recruiting | 33 |
| 2025-09-30 est. | P2/P3 | AVVA Pharmaceuticals Ltd. | NCT06835361 Efficacy and Safety of Clotrimazole+Lactulose Vaginal Suppositories Vs. Clotrimazole Monotherapy in Adult Women with Candidal Vaginitis/Vulvovaginitis | Candidal Vulvovaginitis (ICD-10 Code: B37.3); Vulvovaginal Candidiasis (VVC) | recruiting | 264 |
| 2025-09-30 | P3 | Pfizer PFE | NCT06890416 A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults | Respiratory Syncytial Virus (RSV) | completed | 526 |
| 2025-09-30 | P2 | Lilac Therapeutics, Inc. | NCT06932146 A Phase 2a Study of LLX-424 in Patients With a History of Kidney Stones | Kidney Stones | completed | 51 |
| 2025-09-30 est. | P2 | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | NCT06948357 Efficacy and Safety of BRIMOCHOL PF and CARBACHOL PF in Chinese Presbyopia Patients | Presbyopia | recruiting | 119 |
| 2025-09-30 est. | P1/P2 | Shanghai Huaota Biopharmaceutical Co., Ltd. | NCT06992687 A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors | Solid Tumors | enrolling by invitation | 30 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.